Jennison Associates
ADAP

Jennison Associates’s Adaptimmune Therapeutics ADAP Stock Holding History

Jennison Associates’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-402,609
Closed -$3.28M – 650
2016
Q2 		$3.28M Sell
402,609
-358
-0.1% -$3.37K ﹤0.01% 519
2016
Q1 		$3.28M Sell
402,967
-83,981
-17% -$687K ﹤0.01% 508
2015
Q4 		$5.87M Buy
486,948
+1,547
+0.3% +$15.2K 0.01% 510
2015
Q3 		$5.81M Buy
485,401
+135,401
+39% +$1.91M 0.01% 533
2015
Q2 		$6.42M Buy
+350,000
New +$6.01M 0.01% 531

Other funds holding ADAP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jennison Associates's ADAP Position: Q3 2016 in Review

Jennison Associates sold out of Adaptimmune Therapeutics (ADAP) in Q3 2016, closing a stake of 402,609 shares — an estimated $3.28M sold.

Jennison Associates first reported a position in ADAP in Q2 2015 and held it in 5 quarters. The position peaked at $6.42M in Q2 2015. 46 funds tracked by Wall St. Rank hold ADAP as of Q3 2016.

  • Jennison Associates reported no remaining Adaptimmune Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Jennison Associates sold 402,609 Adaptimmune Therapeutics shares in Q3 2016, an estimated $3.28M.
  • Jennison Associates first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 5 quarters.
  • Jennison Associates's Adaptimmune Therapeutics position peaked at $6.42M in Q2 2015.
  • 46 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2016.

Based on Jennison Associates's 13F filing for Q3 2016, filed 1 Nov 2016.